(Q39362814)

English

A novel DNA/peptide combined vaccine induces PSCA-specific cytotoxic T-lymphocyte responses and suppresses tumor growth in experimental prostate cancer

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

A novel DNA/peptide combined vaccine induces PSCA-specific cytotoxic T-lymphocyte responses and suppresses tumor growth in experimental prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

0 references

0 references

author name string

Ke-qin Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Fei Yang

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Jin Ye

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Man Jiang

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Yong Liu

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Feng-shuo Jin

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Yu-zhang Wu

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

17 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

79

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1410.e7-13

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Synthetic DNA delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Transfection using synthetic peptides: comparison of three DNA-compacting peptides and effect of centrifugation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Mimovirus: a novel form of vaccine that induces hepatitis B virus-specific cytotoxic T-lymphocyte responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

The cell biology of antigen presentation in dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Improving T cell therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Tumor microenvironment: hypoxia and buffer capacity for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.02.011

7 January 2021

Identifiers

10.1016/J.UROLOGY.2012.02.011

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39362814&oldid=1823039925"